(VIANEWS) – Cigna (CI), Surgery Partners (SGRY), Virco Manufacturing Corporation (VIRC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Cigna (CI)
20.2% sales growth and 11.79% return on equity
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Earnings Per Share
As for profitability, Cigna has a trailing twelve months EPS of $17.4.
PE Ratio
Cigna has a trailing twelve months price to earnings ratio of 20.92. Meaning, the purchaser of the share is investing $20.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.79%.
Previous days news about Cigna(CI)
- According to Zacks on Monday, 1 April, "Enhancing the array of healthcare options, some better-ranked and promising stocks in the Medical sector are Universal Health Services, Inc. (UHS Quick QuoteUHS – Free Report) , The Cigna Group (CI Quick QuoteCI – Free Report) and Health Catalyst, Inc. (HCAT Quick QuoteHCAT – Free Report) , each carrying a Zacks Rank #2 (Buy) at present. "
2. Surgery Partners (SGRY)
9.3% sales growth and 4.07% return on equity
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Earnings Per Share
As for profitability, Surgery Partners has a trailing twelve months EPS of $-0.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.07%.
Sales Growth
Surgery Partners’s sales growth is 5% for the present quarter and 9.3% for the next.
Volume
Today’s last reported volume for Surgery Partners is 595309 which is 35.9% below its average volume of 928732.
Yearly Top and Bottom Value
Surgery Partners’s stock is valued at $28.88 at 06:22 EST, way under its 52-week high of $45.79 and way higher than its 52-week low of $22.05.
3. Virco Manufacturing Corporation (VIRC)
8.9% sales growth and 35.9% return on equity
Virco Mfg. Corporation engages in the design, production, and distribution of furniture for the commercial and education markets in the United States. It offers seating products, including 4-leg chairs, cantilever chairs, tablet arm chairs with work surfaces and compact footprints, steel-frame rockers, stools, series chairs, stack and folding chairs, hard plastic seating, upholstered stack and ergonomic chairs, and plastic stack chairs. The company also provides folding, activity, office, computer, and mobile tables; and computer furniture, such as keyboard mouse trays, CPU holders, support columns, desks and workstations, specialty tables, instructor media stations and towers, and other products. In addition, it offers chair desks, combo units, and tablet arm and caster units, as well as a returns and credenzas. Additionally, the company provides administrative office furniture, including desks, returns, bookcases, storage cabinets, and other items, as well as wardrobe tower cabinets, file credenzas, and mobile pedestals; laboratory furniture comprising steel-based science tables, table bases, lab stools, and wood-frame science tables; mobile furniture, including mobile tables for cafeterias, mobile cabinets, and mobile chairs for school settings and offices; and handling and storage equipment, as well as manufactures stackable storage trucks. It serves educational institutions, convention centers and arenas, hospitality providers, government facilities, and places of worship through its sales and support teams, and dealer network. Virco Mfg. Corporation was founded in 1950 and is headquartered in Torrance, California.
Earnings Per Share
As for profitability, Virco Manufacturing Corporation has a trailing twelve months EPS of $1.73.
PE Ratio
Virco Manufacturing Corporation has a trailing twelve months price to earnings ratio of 6.15. Meaning, the purchaser of the share is investing $6.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.9%.
Volume
Today’s last reported volume for Virco Manufacturing Corporation is 67071 which is 69.66% below its average volume of 221091.
Sales Growth
Virco Manufacturing Corporation’s sales growth is 4.9% for the present quarter and 8.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 152% and a negative 33.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 265.3M for the twelve trailing months.
4. LeMaitre Vascular (LMAT)
8.3% sales growth and 10.64% return on equity
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.34.
PE Ratio
LeMaitre Vascular has a trailing twelve months price to earnings ratio of 49.58. Meaning, the purchaser of the share is investing $49.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.64%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.4%, now sitting on 193.48M for the twelve trailing months.
Moving Average
LeMaitre Vascular’s worth is above its 50-day moving average of $62.26 and way above its 200-day moving average of $58.35.
Earnings Before Interest, Taxes, Depreciation, and Amortization
LeMaitre Vascular’s EBITDA is 7.22.
5. Chimera Investment Corporation (CIM)
7% sales growth and 4.83% return on equity
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in a portfolio of mortgage assets, including residential mortgage loans, agency and non-agency residential mortgage-backed securities, agency mortgage-backed securities secured by pools of commercial mortgage loans, and other real estate related securities. It has elected to be taxed as a REIT and would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its shareholders. The company was incorporated in 2007 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Chimera Investment Corporation has a trailing twelve months EPS of $0.23.
PE Ratio
Chimera Investment Corporation has a trailing twelve months price to earnings ratio of 19.65. Meaning, the purchaser of the share is investing $19.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.83%.
6. Pro-Dex (PDEX)
6.2% sales growth and 10.68% return on equity
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Pro-Dex has a trailing twelve months EPS of $0.84.
PE Ratio
Pro-Dex has a trailing twelve months price to earnings ratio of 20.41. Meaning, the purchaser of the share is investing $20.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.68%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 2.8% and a negative 14.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 48.24M for the twelve trailing months.
